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ABSTRACT 
Background and Aim:  A substantial proportion of pediatric liver transplant recipients develop 
subclinical chronic allograft injury.  We studied whether there are distinct patterns of injury based on 
histopathology features and identified associated immunological profiles.  
 
Methods:  We conducted a cross-sectional study of 157 stable, long-term pediatric recipients of 
transplanted livers (70 boys; less than 6 years old; mean 8.9±3.46 years after liver transplant) who 
underwent liver biopsy analysis from August 13, 2012 through May 1, 2014. Subjects received livers 
from a living or deceased donor and had normal results from liver tests for more than 4 years after 
receiving transplant. Liver biopsies were scored by a central pathologist; an unsupervised hierarchical 
cluster analysis of histologic features was used to sort biopsies into 3 clusters. We conducted 
transcriptional and cytometric analyses of liver tissue samples and performed a systems biology analysis 
that incorporated clinical, serologic, histologic, and transcriptional data.   
 
Results:  The mean level of alanine aminotransferase in subjects was 27.6±14.57 U/L and the mean level 
of gamma-glutamyl transferase was 17.4±7.93 U/L. Cluster 1 was characterized by interface activity 
(n=34), cluster 2 was characterized by periportal or perivenular fibrosis without interface activity (n=45), 
and cluster 3 had neither feature (n=78). We identified a module of genes whose expression correlated 
with levels of alanine aminotransferase, class II donor-specific antibody, portal inflammation, interface 
activity, perivenular inflammation, portal and perivenular fibrosis, and cluster assignment. The module 
was enriched in genes that regulate T-cell mediated rejection (TCMR) of liver and other transplanted 
organs. Functional pathway analysis revealed over-representation of TCMR gene sets for cluster 1 but 
not clusters 2 or 3.  
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Conclusion: In an analysis of biopsies from an apparently homogeneous group of stable, long-term 
pediatric liver transplant recipients with consistently normal results from liver tests, we found evidence 
of chronic graft injury (inflammation and/or fibrosis). Biopsies with interface activity had a gene 
expression pattern associated with TCMR. 
 
Key words:  ALT, DSA, immune response, prognostic factor 
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There are now thousands of long-term pediatric liver transplant recipients who apparently enjoy 
excellent health with no biochemical evidence of allograft injury.  While this success is worthy of 
celebration, it has also generated new questions as to how best to care for these young patients.  The 
goal of securing excellent health over many decades requires constant consideration of optimal 
immunosuppression to ensure efficacy while minimizing toxicity.  The risks associated with low dose but 
chronic immunosuppression have been described
1-7
 leading to substantial efforts directed at drug 
minimization.  Indeed, several prospective, multicenter clinical trials have reported complete 
discontinuation of immunosuppression without progressive allograft damage in select adult and 
pediatric recipients.
8-11
 In contrast, multiple centers around the world have reported that liver allografts 
of patients maintained on standard of care immunosuppression frequently harbor subclinical 
inflammation and/or fibrosis.
12-18
 Moreover, the prevalence and severity of allograft histopathology has 
been reported to increase over time such that, 10 years after transplant, normal histology may be 
present in only 30% of patients while bridging fibrosis or cirrhosis may approach 60%.
13, 15, 16 
Together, 
these reports have suggested that the observed abnormalities reflect an active and ongoing immune 
response, implicating chronic but imprecisely-defined immune mechanisms.
13, 16, 19-24
 Consequently, 
clinicians have been left with a challenging quandary when managing stable patients with consistently 
normal results of liver tests on modest immunosuppression doses: reduce immunosuppression at the 
risk of exacerbating silent, immune-mediated allograft injury, stay the course with uncertainty as to 
whether dosing is appropriate, or escalate immunosuppression unnecessarily, increasing the risk of 
known toxicities.  
 
Based on the contradictory literature regarding optimal immunosuppression for pediatric liver 
transplant recipients who appear stable by clinical and biochemical criteria, we hypothesized that these 
patients are not homogeneous but would sort into distinct histopathological phenotypes reflecting 
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specific mechanisms of chronic graft injury. The aim of this study was to identify these phenotypes and 
elucidate their associated immunologic profiles.  We utilized prospectively collected data and 
biospecimens at the time of screening for participation in iWITH (NCT01638559), a prospective, 
multicenter, North American trial of immunosuppression withdrawal for stable pediatric liver transplant 
recipients.  We believe that a clear description and plausible explanation of histopathological 
phenotypes can have an immediate impact on clinical decision-making and inform the future design of 
rational interventions to maximize allograft longevity.   
 
METHODS 
 
Study Design 
We carried out a cross sectional study using data (donor, recipient and transplant) and biospecimens 
collected at the time of liver biopsy, the final eligibility assessment for participation in iWITH 
(NCT01638559), an immunosuppression withdrawal trial conducted at 12 pediatric liver transplant 
centers in North America (Table 1).  The analysis population included all 157 patients who provided age-
appropriate informed assent and consent (parent/legal guardian) to iWITH and underwent a liver biopsy 
between August 13, 2012 and May 1, 2014.  
 
Subjects:  Key Inclusion/Exclusion Criteria 
Subjects (<18 years) were ≥4 years after primary living or deceased donor liver transplantation for non-
viral and non-autoimmune liver disease at ≤6 years of age who underwent screening liver biopsy for 
iWITH.  Participants were required to have alanine aminotransferase (ALT) and gamma-glutamyl 
transferase (GGT) consistently less than 50 IU/L based on medical record review by the site principal 
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investigator and to be stably maintained on calcineurin inhibitor monotherapy without rejection during 
the preceding two years (Figure 1). 
Routine Histology, C4d Scoring, Multiplex Quantum Dot (Qdot) Immunolabelling, and Automated 
Image Analysis 
High resolution 40Xwhole slide images (WSI) of formalin-fixed, paraffin-embedded, H&E and Masson’s 
trichrome-stained 4μm tissue sections of eligibility liver biopsies were prospectively scored for 42 
histopathologic criteria by a central pathologist without knowledge of any clinical or serological data 
other than the date of transplantation and original disease.  Fibrosis was assessed in several ways: Ishak 
stage (0-6), individual compartmental scores (periportal, sinusoidal, and perivenular; 0-3 each), 3-
compartment sum (0-9) known as the liver allograft fibrosis score (LAFSc)
16
 and quantitatively using a 
combination of pixel area morphometry and/or tissue tethered cytometry
25
 after Qdot multiplex panel 
immunostaining [trichrome and smooth muscle actin (SMA) staining] (Supplementary Figure 1).  C4d 
deposition was evaluated on frozen biopsies using indirect immunofluorescence staining for C4d (mouse 
monoclonal Quidel, San Diego, CA, 1:50) in distinct vascular endothelial compartments and surrounding 
stroma (portal vein and capillary, portal stroma, hepatic artery, sinusoid, central vein and stroma); each 
was separately scored (0=none; 1=minimal; 2=focal; 3=diffuse) and summed for a total C4d score (0-18).  
Batched slide sets were multiplex-stained and evaluated as described in the Supplementary Methods.    
 
Derivation of Histopathological clusters 
Subjects’ histologic scores were classified by an unsupervised hierarchical cluster analysis using Ward’s 
minimum-variance method with standardized data points.  Ten features were initially considered, but 
only 5 exhibited sufficient variability to be considered further: interface activity, perivenular fibrosis, 
fibrosis stage, lobular inflammation, and portal inflammation.  Subjects were categorized into 3 clusters 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
using 3, 4 and 5 variable models and results were compared to determine the best classification model 
using 3 criteria, R square, cubic clustering, and pseudo-F statistic, to determine goodness of fit.  
 
Analysis of liver tissue gene expression data 
Affymetrix U219 microarray data was available from 133 of the 157 liver biopsies and analyses were 
batched to minimize bias. Differential expression was computed employing Significant Analysis of 
Microarray (SAM)
26
and expressed as False Discovery Rate (FDR).  We used Weighted Gene Correlation 
Network Analysis (WGCNA; software package available from R
28
)
27
 to identify the key biological 
networks associated with the demographic, clinical serological and histological features of the study 
subjects. This is a widely used, unsupervised, and exploratory data mining technique that reduces the 
multi-dimensionality of the gene expression dataset by defining modules of co-expressed genes and 
integrates external variables (e.g. clinical or histological traits) by establishing weighted correlations with 
the gene modules. Validation gene expression experiments for a set of 800 pre-defined genes were 
conducted on 148 RNA samples utilizing a Nanostring nCounter platform. A detailed description of the 
gene expression experiments is provided in the Supplementary Methods. 
 
Autoantibody assessment  
Samples isolated from plasma or serum collection tubes were assayed for quantitative serum 
immunoglobulin G (IgG), α-nuclear antibodies (ANA), α-smooth muscle antibodies (ASMA), α-
angiotensin II type 1 receptor (AT1R) antibody and α-endothelin type A receptor (ETAR) antibody. (EIA-
AT1RX/EIA-ETAR, One Lambda, Canoga Park, CA). 
 
HLA typing and alloantibody characterization  
HLA typing data was retrieved from United Network for Organ Sharing for 106 deceased and 24 living 
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donors.  HLA typing was performed by SSP or SSO (One Lambda, Canoga Park, CA) for 20 living donors 
and 154 recipients.  HLA typing data was unavailable for 7 donors (4 deceased; 3 living) and 3 recipients.  
HLA mismatch data is presented in Supplementary Table 1.   
Screening and specificity analysis for donor-specific HLA antibody (DSA) against HLA antigens was 
determined using FlowPRA®Screening and LabScreen® Single Antigen™ (One Lambda, Canoga Park, CA).  
FlowPRA® was acquired on a FACSCanto II (Becton-Dickinson, San Jose CA.) and Single Antigen™ bead 
assessments were performed on the LABScan 200 instrument (Luminex Corp. Austin, TX).  Samples with 
sufficient volume were also tested using C1qScreen™ (One Lambda Inc., Canoga Park, CA, USA) acquired 
on a LabScan3D instrument (Luminex Corp., Austin, TX).  HLA pattern analysis and bead mean 
fluorescence intensity (MFI) >2000 for LabScreen® and >5000 for C1qScreen™ determined positivity.  
Only class II DSA data are presented as the preponderance of literature indicates their primacy in 
chronic allograft damage.
22, 28, 29
 HLA-DRB1-DQB1-DQA1 linkage-disequilibrium data was used to assign 
donor specificity for HLA-DQ antibodies for subjects with limited donor HLA-DQ typing.   
 
Statistical Analysis 
Descriptive statistics including mean, standard deviation (SD), and quartiles were determined for 
continuous variables and frequencies and percentages were determined for categorical variables.  
Comparisons of categorical variables between two groups used the Fisher exact test while comparisons 
of continuous variables with two groups used the two-sample t-test. Comparisons of continuous 
variables with more than two groups used ANOVA. 
 
Multivariable logistic regression analyses were used to study associations between histological features, 
C4d scores and serological profiles.  Univariable and multivariable logistic regression analyses were used 
to identify selected predictors of subjects’ histologic cluster assignment among clinical and serologic 
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factors along with their interactions.  Small amounts of missing data in risk factors were accommodated 
in the multivariable analyses by case-wise deletion. Significant predictors at the 0.10 level in the 
univariable analyses were included in the multivariable models.  Backwards variable elimination using 
0.10 as the threshold for retention resulted in the final multivariable model.  The model was internally 
validated using 1000 bootstrapped resamples to produce an optimism-adjusted area under the curve. 
Statistical significance was set at an alpha level of 0.05. All statistical analyses were performed using SAS 
software (version 9.4, SAS Institute, Inc., Cary, NC, USA).  All authors had access to the study data and 
reviewed and approved the final manuscript. 
 
RESULTS 
Characteristics of enrolled subjects  
Subjects (79 boys; 84% white) were a mean (SD) 1.8 (1.70) years old at transplant and 10.7 (3.50) years 
old at enrollment (Table 1).  They underwent living (n=47; 30%) or deceased [whole n=73 (47%); partial 
n=37 (24%)] donor liver transplant predominantly for biliary atresia (55%).  A modest proportion 
received induction immunosuppression (n=21; 13%).  At enrollment, all were on calcineurin inhibitor 
monotherapy with mean (SD) ALT of 27.6 (14.57) U/L and GGT of 17.4 (7.93) U/L.   
 
Inflammation, fibrosis, and C4d scores for 157 eligibility biopsies 
The 157 eligibility biopsies were assessed for necroinflammatory activity and fibrosis (Figures 2A and 
2B).  Lymphocytic inflammation was common in the portal/periportal area (59% mild; 5% moderate) but 
less so in the perivenular (17% mild) area.  A minority showed interface activity (21% mild; 1% 
moderate), lobular (23% mild; 1% moderate) or perivenular inflammation (17% mild).  As expected, 
inflammation and fibrosis typically occurred together and were spatially associated.  Biopsies with portal 
inflammation and interface activity had higher Ishak fibrosis stages while biopsies with perivenular 
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inflammation had higher perivenular fibrosis scores.  However, fibrosis and inflammation were 
occasionally disconnected: some biopsies showed mild or moderate portal or perivenular fibrosis but no 
inflammation while others showed mild portal inflammation without interface activity and low Ishak 
fibrosis stage and LAFSc. 
 
C4d scores, total and by compartment, are shown in Supplementary Figures 2A and 2B.  The two stromal 
compartments, portal and perivenular, were most frequently positive.  Portal stromal staining was 
associated with portal inflammation (p=0.03); perivenular stromal staining was associated with 
perivenular inflammation (p=0.009) (Supplementary Table 2).  The distribution and intensity of 
microvascular endothelial cell C4d staining followed both HLA class II target antigen expression
30-32
 and 
blood flow:  portal capillaries > sinusoids > central vein.  No other significant associations with routine 
histopathology findings were detected.  
 
Auto- and alloantibody profiles of subjects 
ANA and ASMA were positive in 26% (34/133) and 4% (5/133), respectively; mean (SD) IgG was 701.0 
(194.95) mg/dL (Table 1; Supplementary Figure 3).  Most subjects were positive for α-AT1R and α-ETAR 
antibodies (68.1% and 66.4%, respectively) with mean (SD) concentrations of 35.9 (21.49) and 35.2 
(21.39) U/mL, respectively.  Subjects positive for ANA were older at study entry with a longer interval 
since transplant.  In contrast, those positive for α-AT1R and α-ETAR antibodies were younger at time of 
study entry with a shorter interval since transplant.  Associations between clinical characteristics and 
autoantibody profile are shown in Supplementary Table 3A.   
 
For class II DSA, 80 of 144 (55.6%) tested subjects were positive with mean (SD) MFI sum of 26,699 
(16,674). Forty-two subjects had a single class II DSA, 28 had 2 class II DSAs, and 10 had 3 or more class 
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II DSAs (Table 1).  Among the 130 class II DSAs identified, 38.5% had MFI >20,000 and 68.5% had 
specificity against DQ antigens.  Thirty-seven of 80 (46.2%) subjects had at least one class II DSA with 
MFI >20,000 (data not shown); eight additional subjects with >1 DSA, had a DSA sum >20,000 MFI (data 
not shown). Finally, among the 80 subjects with class II DSA, 61 subjects had sufficient serum to test 
complement binding capacity.  The majority (78.7%) tested positive, with mean C1q MFI >20,000; data 
not shown).  Notably, no associations were identified between class II DSA parameters and clinical 
characteristics including age at transplant or study entry, interval since transplant, living or deceased 
donor recipient, or history of previous rejection (Supplementary Table 3B).  
 
Associations between serological profiles, histological features, and C4d scores 
Autoantibody parameters (quantitative IgG, ANA, ASMA, α-AT1R, and α-ETAR) in isolation did not show 
any association with either histological features or C4d scores.  For analyses of class II DSA, we selected 
the sum of class II DSA MFI as the representative variable after testing positive/negative, maximum, and 
sum.  A model including all serological variables confirmed the strong and dominant association 
between class II DSA MFI sum >20,000 and histological features as well as C4d scores (Supplementary 
Table 4).  Compared to those with no class II DSA, those with class II DSA MFI sum >20,000 were at 
increased risk of higher Ishak fibrosis stage (OR 4.53; 95% CI 1.78-11.53; p=0.001), portal inflammation 
grade (OR 3.59; 95% CI 1.30-9.93; p=0.01), and C4d scores [portal capillary (OR 5.11; 95% CI 1.98-
13.20;  p<0.001), sinusoidal (OR 4.40; 95% CI 1.49-12.98; p=0.007; total (OR 4.73; 95% CI 1.95-11.48; 
p<0.001)].  
 
157 biopsies sort into three distinct histopathological clusters 
An unsupervised hierarchical cluster analysis identified three clusters based on three histological 
features (Figure 3).  Cluster 1 (n=34) was defined by portal inflammation with interface activity, often 
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associated with variable degrees of fibrosis; cluster 2 (n=45) was characterized by significant Ishak 
and/or perivenular fibrosis but without interface activity; cluster 3 (n=78) were near normal, exhibiting 
neither interface activity nor significant fibrosis (Figure 3A).  As evident in the constellation plot, cluster 
1 clearly diverges from clusters 2 and 3 (Figure 3B).  Given the reported association of DSA with chronic 
graft injury, we compared the prevalence of class II DSA among the clusters. When compared to cluster 
2 and 3, a greater proportion of subjects in cluster 1 had class II DSA. The mean class II DSA MFI was 
higher in cluster 1 versus cluster 2 or 3.  Moreover, a higher percentage of subjects in cluster 1, 
compared to clusters 2 and 3, had class II DSA MFI maximum >20,000 and class II DSA MFI sum >20,000 
(Supplementary Figures 4A and 4B). 
 
Quantitative determination of fibrosis, APCs, leukocytes, and APC: leukocyte pairings  
Differences among the three histopathological clusters were next explored utilizing 
immunohistochemical and multiplex staining.  Fibrosis severity, as quantified by both trichrome and 
SMA staining area, showed the expected trend among clusters (clusters 1 and 2 > cluster 3), but the 
differences were not statistically significant (data not shown).  Cell counts within virtual antigen-
presenting foci, which largely correspond to portal tracts (Methods; Figure 4A-C), readily distinguished 
the clusters.  APCs (CD34-/CD45-/class II+), leukocytes (CD34-/CD45+(high)/class II+/-), and APC-
leukocyte pairings, defined as an APC within 5 microns of a leukocyte, were quantified and compared.  
The number of APCs was significantly higher in clusters 1 and 2 compared to cluster 3 (Figure 4D).  Total 
leukocyte counts were distinctly higher in cluster 1 but similar in clusters 2 and 3 (Figure 4E).  The 
number of APC-leukocyte pairings differed among clusters, being highest in cluster 1 and lowest in 
cluster 3 (Figure 4F).  Analyses over the total biopsy area, as opposed to the virtual antigen-presenting 
foci, showed less significant differences among the clusters (data not shown). 
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The histopathological features defining the three clusters are associated with a distinct module of co-
expressed genes 
To further identify the biological underpinnings of the subclinical histological and immunohistochemical 
abnormalities, we conducted whole genome transcriptional analysis of the liver tissue samples and 
applied WGCNA to identify modules of co-expressed genes that were correlated with demographic, 
clinical, serological and histological traits of interest. Out of the thirty-three distinct modules identified, 
one module comprising 194 genes, which we will refer to as the “salmon” module (Figure 5A; black 
arrow) showed significant correlation with cluster assignment, class II DSA, interface activity, Ishak 
fibrosis stage, portal inflammation, perivenular fibrosis, perivenular inflammation, serum ALT and, 
importantly, was not influenced by clinical confounders such as recipient age or time after transplant. 
This module of 194 genes (Supplementary Table 5) was enriched in pathways related to cytokine-
cytokine receptors, chemokines, and allograft rejection, among others (Figure 5B).  Moreover, 50 of the 
194 genes had been previously described as being associated with T cell mediated rejection (TCMR) in 
microarray studies involving liver, kidney, lung, or heart transplantation (e.g. CXCL9, CXCL10, HLA-DOB, 
CD3E, GZMB, PRF1, CD74).
33-35
 The overall transcript levels of this selected gene module across the 
whole liver tissue microarray data set significantly correlated with the LAFSc, suggesting a potential 
pathogenic role of these genes in liver allograft fibrosis (Figure 5C).   
 
Transcriptional pathways involved in TCMR differentiate cluster 1 from clusters 2 and 3 
To better understand the differences among the three histological clusters we conducted pairwise 
comparisons of their transcriptomes. Cluster 1 significantly differed from cluster 3 and, to a lesser 
degree, from cluster 2. In contrast, clusters 2 and 3 only showed minimal transcriptional differences 
(Figure 5D).  These results and, in particular, the lack of significant differences in pro-inflammatory gene 
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expression between clusters 2 and 3 were confirmed on a Nanostring platform (Supplementary Figure 5 
and Supplementary Tables 6A-C).  
 
To identify the pathways associated with the differential gene expression between cluster 1 and clusters 
2 and 3, we conducted functional pairwise analysis employing the QuSAGE method on a set of 
transcriptional pathways known to be involved in allograft immunopathogenesis across a variety of 
clinical and animal transplant settings.  As a relevant control, we also included a 13-gene signature 
previously described as highly specific for TCMR in stable liver recipients undergoing 
immunosuppression withdrawal (Supplementary Table 7).
33
 The liver rejection gene set was significantly 
associated with cluster 1 but not clusters 2 or 3.  In addition, the following gene sets known to be 
involved in TCMR across a variety of clinical and experimental settings were also over-represented in 
cluster 1: GRIT1 (IFN-γ dependent rejection-associated transcripts), QCAT (cytotoxic T lymphocyte 
associated transcripts), TCB (T cell specific transcripts), and BAT (B cell specific transcripts).  Cluster 1 
was also significantly enriched in the IGT gene set (immunoglobulin associated transcripts) as compared 
to clusters 2 and 3, and in the MCAT gene set (mast cell associated transcripts) as compared to cluster 3, 
both of which are known be associated with allograft fibrosis but not with rejection.
35
 IGT was the only 
gene set over-represented in cluster 2 as compared to cluster 3 (Figure 5E).   
 
We conducted a more extensive pathway analysis to better delineate the functional differences 
between cluster 2 and 3. The two clusters significantly differed in the over-representation of canonical 
pathways involved in fibrogenesis. In addition, cluster 2 was significantly enriched in a gene set specific 
for stellate cells whose expression has been associated with survival in non-transplanted patients with 
chronic liver disease
36
.  In contrast, only minimal differences in inflammatory canonical pathways 
between the two clusters were noted (Supplementary Table 8). 
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To explore the impact of circulating class II DSA on the molecular profile of the liver allograft, we 
employed the Nanostring dataset to compute the liver gene expression differences between class II DSA 
positive versus negative individuals across the study cohort (Supplementary Table 9).  The results greatly 
overlapped with the expression differences between cluster 1 and the other two clusters, likely 
reflecting the different prevalence of class II DSA among the three clusters.  However, after fitting a 
linear model incorporating CD45+ cells to account for the imbalance in the degree of inflammatory 
infiltrate, we identified CCL18 and CXCL9 as transcriptional markers independently associated with class 
II DSA (FDR 0.0007 and 0.009, respectively).  
 
ALT and MFI sum of class II DSA MFI >20,000 independently predict assignment into cluster 1 
Finally, the mechanistic insight suggesting that subjects in cluster 1 are experiencing alloimmune graft 
injury motivated us to utilize logistic regression analyses to identify clinical and/or serological risk factors 
(Table 2).  Univariable models identified deceased donor (OR 4.03; 95% CI 1.33-12.20; p=0.01), non-
biliary atresia transplant indication (OR 2.38; 95% CI 1.08-5.26; p=0.03), decreased time between 
transplant and eligibility biopsy (OR 0.88 per year increment; 95% CI 0.78-0.99; p=0.03) and increased 
ALT (OR 1.06 per 1 IU/L increment; 95% CI 1.02-1.11; p=0.009) as associated with assignment into 
cluster 1 versus clusters 2 and 3.  ANA and ASMA positivity were not associated with cluster 1 
assignment but both α-AT1R (OR 1.03; 95% CI 1.01-1.05; p=0.01) and α-ETAR antibodies (OR 1.03; 95% 
CI 1.00-1.05; p=0.02) were associated with cluster 1 assignment.  Class II DSA presence (OR 2.90; 95% CI 
1.14-7.34; p=0.02) was also associated with assignment into cluster 1.  The association was stronger 
when class II DSA MFI sum was >20,000 (OR 4.49; 95% CI 1.67-12.14; p=0.003) and strongest when class 
II DSA maximum was >20,000 (OR 5.55; 95% CI 2.00-15.44; p=0.001).  We selected to use the sum of 
class II DSA MFI as the class II DSA variable.  The final multivariable model shows that two factors, ALT 
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(OR 1.07 per U/L; 95% CI 1.02-1.13; p=0.01) and the sum of class II DSA MFI >20,000 (OR 5.11; 95% CI 
1.82-14.41; p=0.002), were independently associated with assignment into cluster 1 versus 2 and 3 
(Table 2).   
 
 
DISCUSSION 
Long-term sustainability of allograft and patient health is the primary challenge facing the liver 
transplant community.  This challenge is undoubtedly the lengthiest and steepest for pediatric 
recipients.  To address this challenge, we conducted a cross-sectional study of well-characterized, stable 
liver transplant recipients who had consented to enter a trial of complete immunosuppression 
withdrawal.  As hypothesized, we were able to define, among this clinically homogeneous cohort, three 
distinct histopathological clusters, differentiated by the presence and severity of interface activity 
and/or fibrosis.  To explore potential mechanism(s) underlying the distinctions among the clusters, we 
employed an unsupervised systems biology approach to analyze the liver tissue transcriptional patterns 
associated with clinical, serological, and histological features.  This strategy allowed an unbiased 
assessment of the important parameters influencing the expression profiles as well as the identification 
of potential confounders.  A module of co-expressed genes dominated by transcripts strongly associated 
with rejection
34, 35
 was significantly correlated with class II DSA, interface activity, and fibrosis. Direct 
comparisons between clusters revealed that rejection-associated transcripts were predominantly 
increased in cluster 1, the cluster characterized by interface activity.  This finding was confirmed at the 
functional pathway level: we showed that IFN-γ-regulated gene signatures known to be associated with 
TCMR in liver, kidney, and heart transplantation were significantly enriched.
35, 37
 The suggestion that 
interface activity may reflect subclinical rejection has implications for the optimal management of 
immunosuppression for this subset of patients that merits future testing.  The approach is clearly 
different from efforts to withdraw immunosuppression for those without interface activity who 
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ultimately participated in the iWITH trial.  Our description of distinct histopathological phenotypes and 
provision of their associated molecular patterns is a necessary step towards the personalization of 
immunosuppression management necessary to simultaneously optimize patient and graft health and 
longevity.  
 
After liver transplantation, it is understood that the inflammatory damage of TCMR is orchestrated by 
effector T cells engaging alloantigen-bearing APCs and parenchymal cells, preferentially in the portal 
areas.
31
 We found that the transcript levels of the set of 194 co-expressed genes directly and 
significantly correlated with the magnitude of leukocyte infiltration.  Furthermore, liver biopsies from 
cluster 1 exhibited the highest number of APC-leukocyte pairings – leukocytes in close proximity to, and 
potentially interacting with, APCs.  Although cluster 1 subjects also had the highest prevalence of class II 
DSA, we did not observe a significant enrichment in intra-graft endothelial or natural killer cell related 
gene signatures, which have been described as selective for antibody-mediated rejection (ABMR) in 
kidney and heart transplantation.
38, 39
 The lack of up-regulation of classic ABMR-specific signatures 
strongly suggests that endothelial damage is not the primary pathogenic feature of the inflammatory 
changes observed in cluster 1 biopsies but does not exclude the involvement of DSA in 
immunopathogenesis.  First, liver, compared to kidney and heart, allografts respond differently to DSA.  
Moreover, the histological features of chronic ABMR in liver transplantation remain incompletely 
defined.
31
 As a result, liver-specific transcriptional signatures discriminating chronic ABMR from TCMR 
cannot be derived.  Second, data from experimental animal models indicate that, in addition to their 
capacity to induce immunopathology by binding HLA molecules in the endothelium and activating 
complement and natural killer cells, alloantibodies can promote allograft rejection by an alternative 
mechanism that enhances the expansion and effector function of donor-specific T cells.40 In support of a 
link between humoral sensitization and anti-donor T cell mediated responses, recent data from kidney 
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transplant patients with chronic ABMR
41
 demonstrate that the magnitude of indirectly-primed CD4+ T 
cell responses (i.e. T cell responses elicited by recipient APCs presenting peptide fragments of donor 
graft antigens) correlates with the progression of kidney allograft dysfunction. Third, our observation 
that class II DSA was associated with expression of T cell chemokines such as CCL8 and CXCL9, after 
adjusting for the magnitude of inflammation, suggests a contributory role of class II DSA to the 
development of liver T cell infiltration. Taken together, these results indicate that patients with 
subclinical histological abnormalities that include interface activity (cluster 1) constitute a distinct 
phenotype that recapitulates the molecular mechanisms described in allograft rejection.  Late subclinical 
histopathological abnormalities are prevalent in many different solid organ allografts and contribute to 
long-term allograft structural decline.
13, 19-23, 28, 29, 42-48
  Whether, in liver transplantation, this is exclusively 
a T cell mediated process, or, more likely, a mixed process influenced by both humoral sensitization and 
T cell alloreactivity cannot as yet be determined.   
 
In contrast to the interface activity characteristics of cluster 1, the pathogenesis of cluster 2 lesions, 
periportal and/or perivenular fibrosis without inflammation, remains more difficult to elucidate.  There 
were only subtle transcriptional differences between clusters 2 and 3 in pro-inflammatory and rejection 
gene sets.  Although cluster 2 compared to cluster 3 biopsies exhibited increased numbers of APCs and 
APC-leukocyte pairings, the differences were smaller than those between clusters 1 and 3.  These small 
differences could reflect fibrotic changes or, alternatively, spatial or temporal sampling issues.  
Nevertheless, in sum, our data suggest that an active alloimmune response may not be the basis for the 
separation of cluster 2 from 3.  Further research is necessary to determine the mechanism(s) underlying 
the “bland” fibrosis characteristic of cluster 2.  
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While this study is the product of a comprehensive mechanistic effort, there remain limitations.  First 
and foremost, the liver biopsies were from a highly selected subset of pediatric liver transplant 
recipients.  The prospective application of extensive inclusion/exclusion criteria specified by iWITH 
resulted in the enrollment of a homogeneous cohort characterized by clinical stability and consistently 
normal liver tests.  Moreover, all subjects necessarily came from participating clinical sites, 12 large 
volume and mature pediatric liver transplant centers specifically selected for experience and 
infrastructure to conduct a complex clinical trial.  Therefore, our study cohort can arguably be described 
as “clinically ideal” and not representative of the general population of pediatric liver transplant 
recipients.  This context, however, may ironically increase the importance of our findings.  It is highly 
likely that our study, underestimates the prevalence of cluster 1 and overestimates the prevalence of 
cluster 3 in the general population.  Second, our study’s cross-sectional design does not shed any light 
on the evolution of the observed histopathological changes either prior to or, perhaps more 
importantly, since the time point studied.  It is now critically important to determine if the 
necroinflammatory changes characteristic of cluster 1 translate into progressive fibrosis that can shorten 
allograft longevity.  Our well-characterized cohort provides the foundation for a future longitudinal 
study based on sequential biospecimens.  Third, the inclusion of deceased donor recipients lacking high 
resolution donor HLA typing data limited the fidelity of the DSA dataset.  The deficits are mitigated, at 
least in part, by the overall harmony of our results with the literature regarding associations between 
class II DSA and chronic inflammatory allograft damage.
13, 19-23, 28, 42-46
  
 
In summary, our data offers a plausible rationale for the chronic, inflammatory changes that have been 
repeatedly described but not explained in apparently stable, long-term pediatric liver allografts.12-18  We 
show, at the molecular level, interface activity connotes subclinical rejection.  Our findings highlight that 
consistently normal results of liver tests may hide a spectrum of histopathology that can only be 
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accurately exposed by tissue examination and support the necessity of liver biopsy to guide personalized 
immunosuppression decision-making.
49
 For patients whose biopsies harbor neither inflammation nor 
fibrosis, immunosuppression dose reduction may be reasonable, based on the consistently reported 
safety of attempted immunosuppression withdrawal.
8, 9, 50
  For patients whose biopsies show fibrosis in 
the absence of inflammation, our data does not support any recommendations.  Lastly, for patients 
whose biopsies show interface hepatitis, our data indicates that dose reduction may be unwise.  
Although the intuitive response may be to escalate immunosuppression, data evidencing the benefit of 
this approach is lacking.  Clearly, the next steps are to delineate the natural history of the 
histopathological phenotypes that we have described which will then inform the design and justify the 
testing of targeted interventions to optimize allograft health and longevity. 
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FIGURE LEGENDS 
Figure 1:  Selection of 157 study participants  
Figure 2:  Key histological features of 157 biopsies 
(A)    Heat map and (B) frequencies of histological features.  
Figure 3:  157 biopsies divide into three histological clusters 
The three variables defining the clusters are Ishak fibrosis stage, interface activity and perivenular 
fibrosis.  
(A) Three-dimensional bubble plot: Bubble size is proportional to the number of observations at that 
coordinate. 
(B) Constellation plot: Each subject is represented by a color-outlined point. Line lengths represent 
distances between clusters and points. Axis scales are relative distance measures. 
Figure 4:  Counts of antigen-presenting cells, leukocytes, and APC-leukocyte pairings in virtual antigen-
presenting foci  
A)   H&E section (left) and multiplex Qdot immunostaining of CD34/CD45/class II panel (right) 
illustrating a “virtual antigen-presenting foci” localized primarily to portal tracts (yellow circles)  
B)  High magnification (white box, Panel A) of an antigen-presenting focus within a portal tract 
illustrating CD34+ portal capillaries in the left panel (green), CD45+(high) leukocytes in the middle 
panel (teal), and a pairing of a CD34-/CD45-/class II+ APC (red) and a CD34-CD45+(high)/class II- 
(teal)/CD34-/CD45+(high)/ class II+ leukocyte (white) pairing in the right panel.  The small white 
circle in the right panel identifies the APC-leukocyte pairing.   
C)  Statistical pairwise comparison of clusters for total APCs (CD34-/CD45-/class II+; red cells; upper 
panel), total leukocytes (CD34-/CD45
+
/class II +/-; white or teal cells; middle panel), and APC-
leukocyte pairings (lower panel).  
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Figure 5: Microarray transcriptional analysis of liver biopsy samples shows that cluster 1 is enriched in 
rejection-associated molecular pathways 
(A)  Weighted gene co-expression network analysis of the liver transcriptome: X-axis: external traits of 
interest; Y-axis: 33 identified gene modules.  The color intensity is proportional to the magnitude of 
the Pearson correlation coefficient. Asterisks denote statistical significance at p value <0.01. The 
black arrow signals the selected “salmon” 194-gene module (Supplementary Table 5).  
(B)  Gene-pathway association network visualizing the relationships between the top 10 KEGG 
pathways and core genes significantly enriched in the 194-gene “salmon” module. The size of the 
circled pathways reflects the associated p values of the terms: more significant pathways are 
larger.  
(C)  Scatter plot and best-fit line showing the correlation between the scaled sum of the normalized 
expression levels of the 194 genes of the “salmon” module and the LAFSc. Dots represent individual 
samples and their color the cluster assignment. r corresponds to the Pearson correlation 
coefficient.  
(D)  Quantile-quantile plots of expected versus observed scores comparing the distribution of 
microarray gene expression values for clusters 1, 2, and 3.  Differentially expressed genes as 
computed by the SAM package deviate from the diagonal. Up-regulated versus down-regulated 
genes at FDR<5% are red open circles in the upper right versus green open circles in the lower left.  
(E)  CI plot displaying the mean and 95% CI of the activity (log2ratio) of each transplantation-related 
gene set of interest plotted and color-coded according to their FDR-corrected p values. 
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Table 1: Characteristics of 157 subjects undergoing iWITH eligibility biopsy 
Characteristic* 
 
 
Donor 
Age (years) 15.7 (15.44) 
Male gender 81 (51.6) 
 
Race (n=132) 
White 105 (79.5) 
Black 19 (14.4) 
Other 8 (6.1) 
Deceased 110 (70.1) 
 
 
 
 
 
Recipient 
Age at transplant (years) 1.8 (1.70) 
Male gender 79 (50.3) 
 
Race (n=152) 
White 128 (84.2) 
Black 11 (7.2) 
Other 13 (8.6) 
 
 
Transplant indication 
Acute Liver Failure 11 (7.0) 
Biliary Atresia 86 (54.8) 
Tumor 8 (5.1) 
Metabolic Liver Disease 18 (11.5) 
Other 34 (21.7) 
 
 
Transplant 
Whole graft 73 (46.5) 
 
Previous rejection episodes 
0 96 (61.1) 
1 40 (25.5) 
2 or more 21 (13.4) 
Time since last rejection (years) 7.3 (3.22) 
 
 
 
 
 
 
 
At Study 
Entry 
Age (years) 10.7 (3.50) 
Time since transplant (years) 8.9 (3.46) 
ALT (U/L) 27.6 (14.57) 
GGT (U/L) 17.4 (7.93) 
Quantitative IgG (n=125; mg/dL) 701.0 (194.95) 
ANA ≥1:40 (n=133) 34 (25.6) 
ASMA = 1:80 (n=133) 5 (3.8) 
α-AT1R antibody (n=119; U/mL) 35.9 (21.49) 
α-ETAR antibody (n=119; U/mL) 35.2 (21.39) 
Class II DSA positive (n=144; MFI ≥2,000) 80 (55.6) 
 
 
Class II DSA (n=80) 
Number of 
DSAs 
1 42 (52.5) 
2 28 (35.0) 
3 or more 10 (12.5) 
Maximum MFI >20,000 37 (46.2) 
MFI sum >20,000 45 (56.2) 
*Continuous variables are summarized using mean and standard deviation (SD). Categorical variables are 
summarized by counts and percentages. 
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Table 2: Clinical and serological factors associated with assignment into cluster 1 
 
Characteristic Reference OR 95% CI P Value
Univariable 
Donor 
Age (per year) 0.98 0.95-1.01 0.14 
Deceased Living 4.03 1.33-12.20 0.01 
 
Recipient 
Female Male 0.47 0.21-1.04 0.06 
Biliary Atresia Other 0.42 0.19-0.93 0.03 
 
 
Transplant 
Whole graft Partial graft 1.89 0.87-4.08 0.11 
Whole graft  
Living graft 
4.06 1.29-12.77 0.02 
Deceased partial graft 3.98 1.14-13.97 0.03 
Induction immunosuppression None 0.55 0.15-1.99 0.36 
 
 
 
 
 
 
 
Study 
Entry 
Recipient age (per year) 0.90 0.81-1.01 0.07 
Time since transplant (per year) 0.88 0.78-0.99 0.03 
ALT (per U/L) 1.06 1.02-1.11 0.009 
GGT (per U/L) 1.02 0.97-1.06 0.51 
ANA ≥ 1:40 Negative 1.62 0.65-4.05 0.30 
ASMA = 1:80 Negative 0.98 0.10-9.15 0.99 
α-AT1R antibody (per U/mL) 1.03 1.01-1.05 0.01 
α-ETAR antibody (per U/mL) 1.03 1.00-1.05 0.02 
 
 
Class II 
DSA 
Positive Negative 2.90 1.14-7.34 0.02 
Maximum MFI ≤ 20,000 No class II 
DSA 
1.32 0.41-4.24 0.64 
Maximum MFI > 20,000 5.55 2.00-15.44 0.001 
MFI sum ≤ 20,000 No class II 
DSA 
1.36 0.40-4.64 0.63 
MFI sum > 20,000 4.49 1.67-12.14 0.003 
Multivariable 
 ALT (per U/L) 1.07 1.02-1.13 0.01 
Class II 
DSA 
MFI sum ≤ 20,000 No class II 
DSA 
1.50 0.43-5.26 0.53 
5.11 1.82-14.41 0.002 MFI sum > 20,000 
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Supplementary Methods 
 
Routine Histology, C4d Scoring, Multiplex Quantum Dot (Qdot®) Immunolabeling, and Automated 
Image Analysis 
Batched slide sets (34 maximum per batch) were multiplex-stained at room temperature on a LabVision 
Autostainer 360, followed by Qnuclear™ Deep Red Stain (Q10363, ThermoFisher/Invitrogen, Carlsbad, 
CA), dehydration through alcohols and xylenes and coverslipping utilizing EcoMount (EM897L, Biocare 
Medical, Pacheco, CA), as previously described
1
.  Briefly, primary antibody labeling (Table below) was 
followed by i) PBS-T washing, ii) detection using an appropriate biotinylated IgG secondary antibody (BA-
1000 or BA-2000, Vector Labs, Burlingame, CA), and iii) streptavidin conjugated Qdot® labeling (605: 
Q10101MP; 655: Q10121MP; 705: Q10161MP; 800: Q10171MP; Molecular Probes, Eugene, OR).   
Blocking was performed between primary antibody applications using Avidin/Biotin Blocking Kit (SP-
2001, Vector Labs, Burlingame, CA) and Serum-Free Protein Block (X090930-2, Agilent/Dako, Santa 
Clara, CA). 
Primary Antibodies 
Antigen 
Company  
(catalog #) 
Dilution 
(into PBS) 
1st incuba-
tion time 
Qdot 
Qdot  
Dilution 
2nd incuba-
tion time 
Mouse α-human CD34 Dako (M7165) 1:100 4 HR 605 or 705 1:50 or 1:250 30 min 
Mouse α-human CD45 Dako (M0701) 1:500 2 HR 705 1:250 30 min 
Rabbit α-human MHCII Abcam (ab157210) 1:1000 2 HR 800 1:500 30 min 
Mouse α-human Ki-67 (MIB-1) Dako (M7240) 1:100 4 HR 705 1:50 30 min 
Mouse α-human SMA Dako (M0851) 1:2000 2 HR 800 1:500 30 min 
 
A Zeiss AxioScan Z.1 (Carl Zeiss, Jena, Germany) setup using a 20x/0.8NA objective, cooled 16-bit sCMOS 
camera (Hamamatsu Photonics, Hamamatsu City, Japan), and HXP-120V metal halide excitation source 
created the multiplex WSI.  Filter sets appropriately matched each fluorophore/Qdot® to maximize the 
emission spectra signal to noise ratio (Semrock, Rochester, NY; Omega, Brattleboro, VT; Chroma, 
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Bellows Falls, VT). Pixel-based quantitative morphometry of trichrome-stained slides calculated the total 
tissue biopsy percentage occupied by fibrosis.  All WSIs were checked for folds, focus quality, and 
optimized staining; suboptimal areas were discarded.  Fully automated tissue-tethered cytometry was 
then performed using internally developed image analysis software (NearCYTE; http://nearcyte.org) that 
co-localizes multiple analytes via a defined nuclear marker and parametric segmentation.  Multiplex 
staining panels included: a) CD34/SMA/Ki-67 (MIB-1) for sinusoidal capillarization, stellate cell 
activation, and proliferating cells (Supplementary Figure 2); and b) HLA class II/CD34/CD45 for extent of 
class II expression, antigen presenting cells (APCs), and total leukocyte load. Only CD45 (high) cells 
(predominantly lymphocytes)
2
 were considered CD45+ and included in the automated morphometric 
analyses. Analyte expression patterns were defined via morphological parameters, such as staining 
intensity, circumferential expansion of the segmented nuclear edges to define cytoplasmic areas, and 
threshold of signal expression per area (nuclear versus cytoplasmic) needed to define “positive” 
classifications. Defined expression patterns were then applied via automated batch processing across all 
slides without human intervention. Classification results were then reviewed as a WSI overlay and/or via 
generated summary statistics.  Following WSI classification, additional spatial-based reporting logic was 
incorporated for pattern discovery (e.g. clustering of known cell phenotypes, structural distances, and 
other spatial characteristics.  For example, “virtual antigen-presenting foci” were defined as circular 
areas (diameter of 100 microns) centered on density-based spatial clusters (DBSCAN, radius=15 microns) 
of ≥5 CD34-/CD45-/class II+ cells, most of which are dendritic cells or monocytes/macrophages. Visual 
inspection of five non-systematically selected biopsies from each cluster showed that the vast majority 
(>85%) of virtual antigen-presenting foci, as expected, overlapped with portal/periportal areas. The 
remaining foci were located mostly in perivenular and rarely in mid-lobular areas. An “APC-leukocyte 
pairing” was defined as a CD34-/CD45-/class II+ cell (APC) located within 5 microns of a CD34-/CD45-
/class II+/-cell (leukocyte).  
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Liver tissue gene expression experiments 
RNA samples (n=151) were extracted from cryopreserved liver tissue samples using TRIzol and hybrid-
ized onto Affymetrix Human Genome U219 96-array plates (Thermo Fisher Scientific, High Wycombe, 
United Kingdom).  We performed quality control using AffyPLM
3
 and excluded samples with a Normal-
ized Unscaled Standard Error >1.05, resulting in 133 evaluable arrays.  Raw expression data were nor-
malized using the robust multi-array algorithm
4
 with a custom probe set definition that mapped probes 
to Entrez Gene IDs
5
.  To eliminate genes with invariant expression levels, only those with a coefficient of 
variation ≥0.034 across all microarrays were considered for downstream analysis.  We used Significant 
Analysis of Microarray
6
 and conducted 1,000 data permutations to identify differentially expressed 
genes and to estimate the False Discovery Rate (FDR).  Differential gene expression was also assessed 
using linear models and empirical Bayes moderated t-statistics (Linear Models for Microarray Analysis, 
LIMMA; R-package software)
7
 with FDRs computed using the Benjamini-Hochberg procedure.  We em-
ployed the Weighted Gene Correlation Network Analysis package available from R
8
 to identify modules 
of co-expressed genes highly correlated with external demographic, clinical, serological and histological 
traits.  Applying a power adjacency function β=4 to the absolute Pearson correlation matrices, we identi-
fied 33 distinct co-expression modules containing from 31 to 5,248 genes each.   
 
Validation gene expression experiments on 148 RNA samples were conducted using the Nanostring 
nCounter platform and a pre-defined PanCancer Immune Profiling Panel containing 770 genes to which 
we added 30 additional genes, selected on the basis of their previously described involvement in rejec-
tion, stellate cell function and liver fibrosis.  Raw data were normalized using the NanoStringNorm pack-
age9 [R using the geometric mean of the  most stable genes (MTMR14, CNOT10, MRPS5, EIF2B4, SF3A3, 
TLK2)].  Differential expression was assessed using the LIMMA package described above.  The statistical 
significance of a priori defined sets of genes representing biological pathways on the microarray-derived 
expression dataset was computed employing Quantitative Set Analysis for Gene Expression (QuSAGE)
10
, 
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using the transplantation-related Pathogenesis-Based Transcript gene sets from the Alberta Transplant 
Applied Genomics Centre (ATAGC; http://atagc.med.ualberta.ca/Research/GeneLists) together with a 
13-gene signature (CCL19, SLC1A3, HMMR, GPNMB, CXCL9, GBP2, HLA-DMA, MMP9, MMP7, TOP2A, 
PLA2G7, FABP5, CD74) previously described as highly specific for T cell mediated rejection in stable liver 
recipients undergoing immunosuppression withdrawal.
11
  To compare the over-representation of biolog-
ical pathways in clusters 1, 2 and 3, we employed Gene Set Enrichment Analysis (GSEA)
12
 and gene sets 
derived from the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Hallmark pathway databases 
available from the Molecular Signatures Database.  GSEA analyses were performed using the GSEAPre-
ranked tool, based on t-statistic and a weighted scoring scheme with 1,000 permutations.  To identify 
KEGG pathways enriched in selected modules of co-expressed genes we employed the enricher function 
from ClusterProfiler R-package for hypergeometric tests
13
 and used the cnetplot method to visualize the 
gene-pathway association networks
14
.  
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Supplementary Figure Legends 
 
Supplementary Figure 1: Multiplex staining and image analysis 
(A)  Example of CD34/Ki-67 (MIB-1)/SMA multiplex stain illustrating a small portal tract in the center 
with a proliferating SMA+/Ki-67 (MIB-1)+ putative periportal stellate cell shown in the lower right 
inset.    
 (B)  Color deconvolution using pixel area morphometry was used to quantify liver fibrosis, shown over-
laid on the original image.   
(C)   Correlation between LAFSc and Trichrome Area/Total biopsy area. 
 
Supplementary Figures 2A and 2B:  C4d scores of 157 eligibility biopsies.   
(A) Heat map and (B) frequencies of C4d scores.   
 
Supplementary Figure 3: Autoantibody profiles of enrolled subjects 
(A)  ANA and ASMA (n=133).  Numbers and percentages are shown.   
(B)  α-AT1R and α-ETAR antibodies (n=119). The threshold defining positive is 17 U/ml.   
 
Supplementary Figure 4: Comparison of class II DSA MFI by cluster 
The bar graph shows the proportion of each cluster for each class II DSA MFI value.  The numbers shown 
are absolute numbers.  
(A)  Maximum detected class II DSA MFI  
(B)  Sum of class II DSA MFI  
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Supplementary Figure 5: Nanostring liver biopsy differential gene expression between clusters 1, 2, 
and 3  
Expression profiles of the 109 genes differentially expressed in at least one comparison at p-value <0.05 
and fold change >1.5 are expressed as a matrix view of gene expression data where rows represent 
genes and columns represent hybridized samples. The intensity of each color denotes the standardized 
ratio between each value and the average expression of each gene across all samples. Red or green col-
ored pixels correspond to an increased or decreased abundance of the mRNA in the indicated sample. 
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